RaQualia Pharma

Stock Market Tokyo Stock Exchange JASDAQ
Security Code 4579
Website RaQualia Pharma Website

Pipelines

Updated on 4 8, 2021

Completed
On planning
On going
Launch
Plan
Project Compound code
(Generic name)
Indication Partnered party Discovery Pre-Clin, Clinical Trial NDA Approval Launch Territory Remarks
Phase 1 Phase 2 Phase 3
PotassiumCompetitive acid blocker
(P-CAB)
RQ-00000004
(Tegoprazan)
IN-12420 [HK inno.N]
LXI-15028 [Luoxin Pharma]
GERD
(ERD/NERD)
Gastric ulcer
H. pylori treatment
-
Completed P1
Japan
HK inno.N
On going P1
USA
Launch (March 2019)
Korea Product name: K-CAB
Co-promotion with Chong Kun Dang Pharmaceutical Corp.
Blockbuster expectation with annual sales of 100 billion won.
NDA
Launch
2022
China Re-contracted: HK inno.N => Luoxin Pharma
Market Size (China): 260 billion yen (2 billion 600 million USD) *Investigation of RaQualia
Preparation NDA
Launch
2021
Vietnam Re-contracted: HK inno.N => Vimedimex Medi-Pharma JSC
Related information
Launch
2021
Mongolia Re-contracted: HK inno.N => Monos Pharma
Launch
2022
Singapore Re-contracted: HK inno.N => United Italian Trading Corporation (UITC)
Preparation NDA
Launch
2022
Indonesia Re-contracted: HK inno.N => Kalbe Farma
Related information
Preparation NDA
Launch
2022
Thailand Re-contracted: HK inno.N => Pond's Chemical Thailand R.O.P.
Philippines Re-contracted: HK inno.N => Metro Pharma Phils
Preparation NDA
Launch
2022 (Mexico)
Latin America
17 countries
(Mexico, Argentina etc.)
Re-contracted: HK inno.N => Laboratorios Carnot
Related information
Europe
ROW ROW: Latin America (Brazil etc.), East European, Middle East
Taiwan
Southeast Asia
CRHR2 antagonist RQ-00490721 Heart failure Nagoya University
(Collaborative Research)
On going
Japan Started an investigation of preclinical efficacy.
Presentation at AHA 2019.
This research plans to complete the research phase from the end of 2019 to 2020. [Reference]
TRPM8 blocker RQ-00434739 Neuropathic pain -
On planning
Japan
P2X7 receptor antagonist RQ-00466479
AK1780 [Asahi Kasei Pharma]
Neuropathic pain Asahi Kasei Pharma
Completed P1
(Country undisclosed)
Global Contracted: Asahi Kasei Pharma => Eli Lilly and Company [Reference]
Diabetic neuropathic medicine, herpes virus infective neuropathic medicine. [Reference]
Selective sodium channel blocker - Analgesia
Pruritus
Maruho Undisclosed Global
- Pain -
Discovery
Japan
Specific Ion Channels - Gastrointestinal Tract EA Pharma Undisclosed Global
Specific Ion Channels - - ASKA Pharmaceutical
(Collaborative Research)
On going
-
Sodium channel Nav1.7 selective blocker RQ-00488738 Pain - - Product of collaboration with XuanZhu Pharma
Protein-Protein Interaction Targets - Pain Interprotein
(Collaborative Research)
On going
-
Idiopathic childhood nephrotic syndrome therapy - Idiopathic childhood nephrotic syndrome Epigeneron
(Collaborative Research)
On going
- Utilize locus-specific chromatin immunoprecipitation (locus-specific ChIP).
5-HT4 partial agonist RQ-00000010 Gastroparesis
Functional dyspepsia
Chronic Constipation
-
Completed P1
UK Mosapride's sales amount of peak tops is 21.2 billion yen (Japan)
Gastroparesis -
Completed
Investigator Clinical Trial
USA Collaboration with Virginia Commonwealth University (VCU) Parkinson's and Movement Disorders Center
RQ-00000009
AAT-009 [AskAt]
Alzheimer's AskAt
(Global)
On planning P2
USA
5-HT2B antagonist RQ-00310941 IBS-D -
Completed P1
UK
Motilin receptor agonist RQ-00201894 Gastroparesis
Functional dyspepsia
Post - operative Ileus
-
On planning P1
Japan
Ghrelin receptor agonist RQ-00000005
(Capromorelin)
AT-002 [Elanco]
Appetite Stimulation: Dog Elanco Animal Health
(Global (Animal))
Launch (October 2017)
USA Product name (Dog): Entyce
Product name (Cat): Elura
Management of Weight Loss with CKD: Cat
Launch (March 2021)
USA
RQ-00433412 Cancer-Related Anorexia/Cachexia Syndrome
Constipation resulting from Spinal Cord Injury
-
On planning
Japan
Ziprasidone RQ-00000003
(Ziprasidone Hydrochloride Monohydrate)
ME2112 [Meiji Seika Pharma]
Schizophrenia Meiji Seika Pharma
Completed P3 (Result: No significant difference)
Japan Market Size (Japan): 160 Billion Yen *Investigation of RaQualia
EP4 antagonist RQ-00000007
(Grapiprant)
AAT-007 [AskAt]
AT-001 [Elanco]
IK-007 [Ikena]
RMX1002 [RMX]
Osteoarthritis: Dog Elanco Animal Health
(Global (Animal))
Launch (USA: 2017, Europe: 2019, Brazil, Japan: 2020)
USA
Europe
Brazil
Japan
Product name: Galliprant
MSS Colorectal Cancer AskAt
(Global (Excluding animal))
USA Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)
Development: Arrys parent company Ikena Oncology
Clinical study with grapiprant in combination with pembrolizumab(anti PD-1 antibody, KEYTRUDA).
Cancer
On going P1
China Re-contracted: AskAt => Ningbo Tai Kang Medical Technology
Development: Ningbo NewBay Medical Technology
Pain
Completed P2a
USA
Completed P1
China Re-contracted: AskAt => RMX Biopharma
Development: 3D Medicines [Reference]
RQ-00000008
AAT-008 [AskAt]
AT-019 [Elanco]
Osteoarthritis etc.
(Animal)
AskAt
(Global)
Started transferring the manufacturing process of the API and early formulation work (early-2019)
USA
Europe
Re-contracted: AskAt => Elanco
Cancer
On planning P1
USA Re-contracted: AskAt => Arrys Therapeutics (Global excluding China and Taiwan)
Development: Arrys parent company Ikena Oncology
On planning P1
China Re-contracted: AskAt => Ningbo NewBay Medical Technology
COX-2 Inhibitor RQ-00317076
AAT-076 [AskAt]
RMX1001 [RMX]
Pain AskAt
(Global)
Completed P2a
USA
On going P1
China Re-contracted: AskAt => RMX Biopharma
Development: 3D Medicines [Reference]
On planning P1
Japan
CB2 receptor agonist RQ-00202730
AAT-730 [AskAt]
OCT461201 [OCT]
IBS AskAt
(Global)
On going
USA Re-contracted: AskAt => Oxford Cannabinoid Technologies (OCT) (Global excluding Japan)
Developmental status
IBD
Neuropathic pain
PoC
All potential indications
On going
Japan

Other Pipelines

Updated on 9 20, 2019

Project Indication Partnered party Territory Remarks
Dalbavancin MRSA Infections - Japan US product name: Dalvance
Anidulafungin Candida Infections - Japan US product name: Eraxis

Other Contracts

Updated on 12 15, 2018

Contractor Contract contents Remarks
H. Lundbeck A/S
(Denmark)
RaQualia Grants Patent License to H. Lundbeck Press release
Shire AG
(Swiss)
RaQualia Grants a Non-Exclusive Patent License to Shire AG For the Use of Ghrelin Receptor Agonist Press release
- RaQualia Pharma Joins DeNA & DeNA Life Science AI-Powered Drug Discovery Research Collaboration Press release

University Collaborative Research

Updated on 3 1, 2021

RaQualia Pharma Industry-Academia Collaborative Research Center

University Department Research theme Remarks
Nagoya University Department of Biochemistry, Graduate School of Medicine Search for selective inhibitors targeting specific enzymes for treatment of refractory neuroblastoma Press release
Department of Cardiology, Graduate School of Medicine Search for selective inhibitors targeting specific proteins for treatment of heart failure Press release
Nagoya City University Department of Biomedical Science, Graduate School of Pharmaceutical Sciences Discovery of novel small molecules for the treatment of Amyotrophic Lateral Sclerosis (ALS) Press release
Department of Bacteriology, Graduate School of Medical Sciences Search for novel therapeutic for macrolide-resistant group A streptococci Press release
Gifu Pharmaceutical University Molecular Pharmacology, Department of Biofunctional Evaluation Evaluation of efficacy of a specific compound on retinal vein occlusion (RVO) Press release
Nagasaki University Institute of Tropical Medicine, National Research Center the Control and Prevention of Infectious Diseases Discovery of novel therapeutic for novel coronavirus infectious disease (COVID-19) Press release

TMRC (subsidiary) Pipeline

Updated on 3 4, 2021

Completed
On planning
On going
Launch
Plan
Project Compound code
(Generic name)
Indication Partnered party Discovery Pre-Clin, Clinical Trial NDA Approval Launch Territory Remarks
Phase 1 Phase 2 Phase 3
TM-411 TM-411
(Tamibarotene)
SY-1425 [Syros Pharmaceuticals]
OP-09 [Ohara Pharmaceutical]
Newly Diagnosed HR-MDS Syros Pharmaceuticals
On going P3
USA Combination with azacitidine. Reference.
Newly Diagnosed Unfit AML
On planning P2
(2H 2021)
USA
Neuroblastoma
(NB)
Ohara Pharmaceutical
On going P1/2
Japan
Acute promyelocytic leukemia
(APL)
Toko Pharmaceutical Industrial
NDA
China
Neutropenia
(NP)
-
Completed
USA

Subsidiary

Updated on 1 29, 2021

Company name
TMRC Co., Ltd.

RaQualia Pharma Business Performance

※ Unit: million yen (Amounts are rounded down to the nearest million yen)
※ Non-consolidated: 2011, 2012, 2015, 2016 year. Consolidated: Other years.

Because of the personal survey, there are cases where the information on this site is "different from the fact" due to business content change or misunderstanding etc.
Therefore, please do not use for investment judgment. Also, this site is not intended to solicit investment.

Advertisements